Se de opdaterede Novo-kursmål
Efter Novo Nordisks regnskab for første kvartal torsdag har en række finanshuse revurderet anbefalinger og kursmål for Novo-aktien. Novo Nordisk stiger fredag 0,8 pct. til kurs 239,70.
![](https://photos.watchmedier.dk/7qtSRbfvbh0IJkJsxk1ySUbJyel7xZ8e1D9L_2GWlcU/resize:fill:960:0:0/plain/https%3A%2F%2Fphotos.watchmedier.dk%2FImages%2Farticle6689230.ece%2FALTERNATES%2Fschema-16_9%2FNovo%2520ny.jpg)
En del af Watch Medier
Efter Novo Nordisks regnskab for første kvartal torsdag har en række finanshuse revurderet anbefalinger og kursmål for Novo-aktien. Novo Nordisk stiger fredag 0,8 pct. til kurs 239,70.
Vær på forkant med udviklingen. Få den nyeste viden fra branchen med vores nyhedsbrev.
NyhedsbrevsvilkårFor abonnenter
For abonnenter
For abonnenter
For abonnenter
For abonnenter
Kvalitetsingeniør GMP Pharma, Krüger
Investor Relations Manager
Medical Director
Quality Engineer for Production
Principal Bioinformatic Scientist, Antibody Technology
Global Head of Rewards
QA Manager GMP
Head of Quality Assurance
Healthcare Compliance Senior Specialist (Associated Director), Ascendis Pharma
Business Development Manager
QA/RA Specialist, Patient Handling Division
Environmental Monitoring Professional
Produktionskemiker
QP delegate Biologics, CMC
Skilled Process Specialist for managing logistic and production processes in SAP
Senior Consultant / Project Manager - Life Science (R&D & Clinical)
Principal Bioinformatic Scientist, Antibody Technology
Governmental Public Affairs & Communications Head
ESG Officer
Material Scientist and Coordinator
Head of OTC Product Development
Principal Quality Assurance Professional – Combination Products
Senior Legal Counsel